Which has stronger valuation and earnings, INVA or CBIO?

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Innoviva $411.33M 4.00 $271.17M $6.01 3.71 Crescent Biopharma $10.84M 43.45 -$153.94M -$10.91 N/A

Does the media refer more to INVA or CBIO?

In the previous week, Innoviva had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Innoviva and 2 mentions for Crescent Biopharma. Innoviva's average media sentiment score of 0.61 beat Crescent Biopharma's score of 0.12 indicating that Innoviva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Innoviva 2 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CBIO or ZBIO more profitable?

Zenas BioPharma's return on equity of -99.99% beat Crescent Biopharma's return on equity. Company Net Margins Return on Equity Return on Assets Crescent Biopharma N/A -103.44% -88.19% Zenas BioPharma N/A -99.99% -58.06%

Does the media refer more to CBIO or ZBIO?

In the previous week, Crescent Biopharma had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 2 mentions for Crescent Biopharma and 1 mentions for Zenas BioPharma. Crescent Biopharma's average media sentiment score of 0.12 beat Zenas BioPharma's score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zenas BioPharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CBIO or NVAX?

In the previous week, Novavax had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 4 mentions for Novavax and 2 mentions for Crescent Biopharma. Novavax's average media sentiment score of 0.43 beat Crescent Biopharma's score of 0.12 indicating that Novavax is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Novavax 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to CBIO or MNKD?

In the previous week, Crescent Biopharma and Crescent Biopharma both had 2 articles in the media. Crescent Biopharma's average media sentiment score of 0.12 beat MannKind's score of -0.13 indicating that Crescent Biopharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral MannKind 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CBIO or LXRX?

In the previous week, Crescent Biopharma and Crescent Biopharma both had 2 articles in the media. Lexicon Pharmaceuticals' average media sentiment score of 0.14 beat Crescent Biopharma's score of 0.12 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crescent Biopharma 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Crescent Biopharma (CBIO) Competitors

$17.09 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$17.11 +0.02 (+0.15%)

As of 07/2/2026 04:37 PM Eastern

Compare

CBIO vs. INVA, ZBIO, NVAX, MNKD, and LXRX

Should you buy Crescent Biopharma stock or one of its competitors? MarketBeat compares Crescent Biopharma with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Crescent Biopharma include Innoviva (INVA), Zenas BioPharma (ZBIO), Novavax (NVAX), MannKind (MNKD), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "biotechnology" industry.

How does Crescent Biopharma compare to Innoviva?

Innoviva (NASDAQ:INVA) and Crescent Biopharma (NASDAQ:CBIO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.

Innoviva has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Crescent Biopharma has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market.

Innoviva currently has a consensus target price of $36.20, suggesting a potential upside of 62.26%. Crescent Biopharma has a consensus target price of $29.00, suggesting a potential upside of 69.69%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, analysts clearly believe Crescent Biopharma is more favorable than Innoviva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Innoviva	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83

99.1% of Innoviva shares are owned by institutional investors. Comparatively, 75.2% of Crescent Biopharma shares are owned by institutional investors. 2.0% of Innoviva shares are owned by insiders. Comparatively, 4.0% of Crescent Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Innoviva had 5 more articles in the media than Crescent Biopharma. MarketBeat recorded 7 mentions for Innoviva and 2 mentions for Crescent Biopharma. Innoviva's average media sentiment score of 0.61 beat Crescent Biopharma's score of 0.12 indicating that Innoviva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Innoviva	2 Very Positive mention(s)	2 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Innoviva has higher revenue and earnings than Crescent Biopharma. Crescent Biopharma is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Innoviva	$411.33M	4.00	$271.17M	$6.01	3.71
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A

Innoviva has a net margin of 119.89% compared to Crescent Biopharma's net margin of 0.00%. Innoviva's return on equity of 33.33% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Innoviva	119.89%	33.33%	22.67%
Crescent Biopharma	N/A	-103.44%	-88.19%

Summary

Innoviva beats Crescent Biopharma on 11 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to Zenas BioPharma?

Crescent Biopharma (NASDAQ:CBIO) and Zenas BioPharma (NASDAQ:ZBIO) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

Crescent Biopharma has a beta of 1.2, meaning that its share price is 20% more volatile than the broader market. Comparatively, Zenas BioPharma has a beta of -0.96, meaning that its share price is 196% less volatile than the broader market.

75.2% of Crescent Biopharma shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by insiders. Comparatively, 22.0% of Zenas BioPharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, Crescent Biopharma had 1 more articles in the media than Zenas BioPharma. MarketBeat recorded 2 mentions for Crescent Biopharma and 1 mentions for Zenas BioPharma. Crescent Biopharma's average media sentiment score of 0.12 beat Zenas BioPharma's score of 0.00 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zenas BioPharma	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crescent Biopharma has higher revenue and earnings than Zenas BioPharma. Zenas BioPharma is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A
Zenas BioPharma	$10M	171.90	-$377.74M	-$8.47	N/A

Crescent Biopharma currently has a consensus target price of $29.00, indicating a potential upside of 69.69%. Zenas BioPharma has a consensus target price of $44.29, indicating a potential upside of 62.64%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Crescent Biopharma is more favorable than Zenas BioPharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Zenas BioPharma	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.56

Zenas BioPharma's return on equity of -99.99% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Zenas BioPharma	N/A	-99.99%	-58.06%

Summary

Crescent Biopharma beats Zenas BioPharma on 10 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to Novavax?

Crescent Biopharma (NASDAQ:CBIO) and Novavax (NASDAQ:NVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, institutional ownership, profitability, analyst recommendations, valuation and dividends.

Crescent Biopharma has a net margin of 0.00% compared to Novavax's net margin of -14.73%. Novavax's return on equity of -14.82% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Novavax	-14.73%	-14.82%	1.23%

Crescent Biopharma has a beta of 1.2, indicating that its stock price is 20% more volatile than the broader market. Comparatively, Novavax has a beta of 2.43, indicating that its stock price is 143% more volatile than the broader market.

Crescent Biopharma currently has a consensus price target of $29.00, indicating a potential upside of 69.69%. Novavax has a consensus price target of $13.00, indicating a potential upside of 33.47%. Given Crescent Biopharma's stronger consensus rating and higher probable upside, equities research analysts clearly believe Crescent Biopharma is more favorable than Novavax.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Novavax	3 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.22

In the previous week, Novavax had 2 more articles in the media than Crescent Biopharma. MarketBeat recorded 4 mentions for Novavax and 2 mentions for Crescent Biopharma. Novavax's average media sentiment score of 0.43 beat Crescent Biopharma's score of 0.12 indicating that Novavax is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Novavax	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

75.2% of Crescent Biopharma shares are owned by institutional investors. Comparatively, 53.0% of Novavax shares are owned by institutional investors. 4.0% of Crescent Biopharma shares are owned by company insiders. Comparatively, 1.6% of Novavax shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Novavax has higher revenue and earnings than Crescent Biopharma. Novavax is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A
Novavax	$1.12B	1.43	$440.30M	-$0.58	N/A

Summary

Novavax beats Crescent Biopharma on 9 of the 17 factors compared between the two stocks.

How does Crescent Biopharma compare to MannKind?

Crescent Biopharma (NASDAQ:CBIO) and MannKind (NASDAQ:MNKD) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, institutional ownership, analyst recommendations and risk.

MannKind has higher revenue and earnings than Crescent Biopharma. MannKind is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A
MannKind	$348.97M	4.00	$5.86M	-$0.07	N/A

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 49.6% of MannKind shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by insiders. Comparatively, 2.6% of MannKind shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Crescent Biopharma has a net margin of 0.00% compared to MannKind's net margin of -6.63%. MannKind's return on equity of -11.21% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
MannKind	-6.63%	-11.21%	-3.92%

Crescent Biopharma has a beta of 1.2, indicating that its share price is 20% more volatile than the broader market. Comparatively, MannKind has a beta of 1.09, indicating that its share price is 9% more volatile than the broader market.

Crescent Biopharma presently has a consensus target price of $29.00, suggesting a potential upside of 69.69%. MannKind has a consensus target price of $8.97, suggesting a potential upside of 98.42%. Given MannKind's higher probable upside, analysts clearly believe MannKind is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
MannKind	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Crescent Biopharma and Crescent Biopharma both had 2 articles in the media. Crescent Biopharma's average media sentiment score of 0.12 beat MannKind's score of -0.13 indicating that Crescent Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
MannKind	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Crescent Biopharma beats MannKind on 9 of the 16 factors compared between the two stocks.

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Crescent Biopharma (NASDAQ:CBIO) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, media sentiment, analyst recommendations and institutional ownership.

Lexicon Pharmaceuticals has higher revenue and earnings than Crescent Biopharma. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Crescent Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Crescent Biopharma	$10.84M	43.45	-$153.94M	-$10.91	N/A
Lexicon Pharmaceuticals	$49.80M	20.69	-$50.34M	-$0.07	N/A

Crescent Biopharma has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -37.46%. Lexicon Pharmaceuticals' return on equity of -18.64% beat Crescent Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Crescent Biopharma	N/A	-103.44%	-88.19%
Lexicon Pharmaceuticals	-37.46%	-18.64%	-11.79%

Crescent Biopharma has a beta of 1.2, suggesting that its stock price is 20% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.05, suggesting that its stock price is 5% more volatile than the broader market.

In the previous week, Crescent Biopharma and Crescent Biopharma both had 2 articles in the media. Lexicon Pharmaceuticals' average media sentiment score of 0.14 beat Crescent Biopharma's score of 0.12 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Crescent Biopharma	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Crescent Biopharma presently has a consensus target price of $29.00, suggesting a potential upside of 69.69%. Lexicon Pharmaceuticals has a consensus target price of $4.55, suggesting a potential upside of 96.12%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Crescent Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Crescent Biopharma	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Lexicon Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

75.2% of Crescent Biopharma shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 4.0% of Crescent Biopharma shares are held by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Crescent Biopharma and Lexicon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

Get Crescent Biopharma News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CBIO vs. The Competition

Export

Metric	Crescent Biopharma	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$470.95M	$3.10B	$7.18B	$12.46B
Dividend Yield	N/A	2.05%	2.67%	6.50%
P/E Ratio	-1.57	20.06	28.00	24.70
Price / Sales	43.45	357.05	533.82	98.68
Price / Cash	N/A	57.49	49.26	57.09
Price / Book	1.19	4.32	10.96	6.46
Net Income	-$153.94M	$64.45M	$3.57B	$337.01M
7 Day Performance	-7.54%	2.97%	2.12%	1.70%
1 Month Performance	-7.31%	3.39%	2.80%	0.68%
1 Year Performance	7.55%	29.07%	33.40%	23.94%

Crescent Biopharma Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CBIO Crescent Biopharma	1.5973 of 5 stars	$17.09 flat	$29.00 +69.7%	+7.6%	$470.95M	$10.84M	N/A	50
INVA Innoviva	3.6329 of 5 stars	$22.71 -1.9%	$36.20 +59.4%	+16.2%	$1.71B	$411.33M	3.78	100
ZBIO Zenas BioPharma	2.8983 of 5 stars	$25.38 -0.7%	$44.29 +74.5%	+171.5%	$1.61B	$10M	N/A	N/A
NVAX Novavax	1.8713 of 5 stars	$9.42 +0.6%	$13.00 +38.0%	+43.3%	$1.54B	$1.12B	N/A	1,990
MNKD MannKind	2.9187 of 5 stars	$4.26 +0.5%	$8.97 +110.5%	+25.4%	$1.31B	$348.97M	N/A	400	Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CBIO) was last updated on 7/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, ZBIO, NVAX, MNKD, and LXRX

How does Crescent Biopharma compare to Innoviva?

Summary

How does Crescent Biopharma compare to Zenas BioPharma?

Summary

How does Crescent Biopharma compare to Novavax?

Summary

How does Crescent Biopharma compare to MannKind?

Summary

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Crescent Biopharma (CBIO) Competitors

CBIO vs. INVA, ZBIO, NVAX, MNKD, and LXRX

How does Crescent Biopharma compare to Innoviva?

Which has more risk and volatility, INVA or CBIO?

Do analysts recommend INVA or CBIO?

Do institutionals & insiders hold more shares of INVA or CBIO?

Does the media refer more to INVA or CBIO?

Which has stronger valuation and earnings, INVA or CBIO?

Is INVA or CBIO more profitable?

Summary

How does Crescent Biopharma compare to Zenas BioPharma?

Which has more risk and volatility, CBIO or ZBIO?

Do insiders and institutionals believe in CBIO or ZBIO?

Does the media refer more to CBIO or ZBIO?

Which has stronger earnings & valuation, CBIO or ZBIO?

Do analysts prefer CBIO or ZBIO?

Is CBIO or ZBIO more profitable?

Summary

How does Crescent Biopharma compare to Novavax?

Is CBIO or NVAX more profitable?

Which has more risk and volatility, CBIO or NVAX?

Do analysts recommend CBIO or NVAX?

Does the media favor CBIO or NVAX?

Do insiders & institutionals believe in CBIO or NVAX?

Which has better valuation and earnings, CBIO or NVAX?

Summary

How does Crescent Biopharma compare to MannKind?

Which has higher valuation and earnings, CBIO or MNKD?

Do insiders and institutionals hold more shares of CBIO or MNKD?

Is CBIO or MNKD more profitable?

Which has more risk & volatility, CBIO or MNKD?

Do analysts recommend CBIO or MNKD?

Does the media refer more to CBIO or MNKD?

Summary

How does Crescent Biopharma compare to Lexicon Pharmaceuticals?

Which has preferable earnings and valuation, CBIO or LXRX?

Is CBIO or LXRX more profitable?

Which has more volatility and risk, CBIO or LXRX?

Does the media favor CBIO or LXRX?

Do analysts rate CBIO or LXRX?

Do insiders & institutionals have more ownership in CBIO or LXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CBIO vs. The Competition

Crescent Biopharma Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools